Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CLS Holdings USA, Inc. (CLSH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0750+0.0061 (+8.85%)
At close: 03:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0689
Open0.0689
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0669 - 0.0750
52 Week Range0.0545 - 0.1850
Volume29,585
Avg. Volume29,814
Market Cap9.616M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.0870
Earnings DateAug 29, 2022 - Sep 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CLSH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CLS HOLDINGS USA INC
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • ACCESSWIRE

    Local Brand City Trees is the #1 Selling Brand in Nevada by Units Sold

    LAS VEGAS, NV / ACCESSWIRE / July 12, 2022 / In an industry dominated by multi-state operators (MSOs), it takes a lot for a local independent name to gain significant brand recognition, let alone reach a number one status above the rest. But when consistent, quality products meet an honest, culture- and education-driven operation, it's no surprise that consumers flock to the small fish in a sea of giants.

  • GlobeNewswire

    CLS Holdings USA, Inc to Host Q3, 2022 Financial Results on April 14, 2022

    LAS VEGAS, April 05, 2022 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating as Cannabis Life Sciences, will host a webcast on Thursday, April 14, 2022 at 5 p.m. ET to discuss the Company's financial highlights for its third quarter of fiscal year 2022. Event:CLS Holdings USA, Inc. Q3 FY 2022 Financial Results WebcastDate:Thursday, April 14, 2022Time:5:00 p.m. Eastern TimeWebcast:https://onlinexperiences.com/La

  • ACCESSWIRE

    Starting Strong: CLS Holdings USA, Inc. Announces January and February 2022 Results With Impressive Growth and Numbers

    LAS VEGAS, NV / ACCESSWIRE / March 15, 2022 / CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating as Cannabis Life Sciences, today announced a strong start to the new year with the release of the financial and operational results for its Nevada wholly owned subsidiaries for January and February 2022.

Advertisement
Advertisement